Discovery of Hepatitis C Snags Nobel Prize in Medicine
Harvey J. Alter, Michael Houghton and Charles M. Rice share the award for identifying the virus behind the blood-borne liver disease
Harvey J. Alter, Michael Houghton and Charles M. Rice share the award for identifying the virus behind the blood-borne liver disease
Proponents say yes, but scientific studies on the effectiveness of this chemical derived from cannabis are a mixed bag
Experts explain why getting vaccinated is important every year—and especially during a pandemic
Advisory groups around the world have released guidance to prioritize healthcare workers and those in front-line jobs
The test was halted when a participant suffered spinal cord damage, and U.S. scientists launched an investigation
U.K. trials of the Oxford and AstraZeneca vaccine have resumed after a brief pause, yet key details of the events have not been released
Scientists urge caution in the global vaccine race as AstraZeneca reports an “adverse event” in a person who received the University of Oxford vaccine
After neutralizing SARS-CoV-2 in cell culture, scientists at the University of Costa Rica are proceeding with human testing
The Trump administration’s Operation Warp Speed program is backing six efforts with the ambitious goal of delivering an effective vaccine by January
Medical ethicist Ezekiel Emanuel discusses a framework for equitably allocating COVID-19 vaccines based on preventing premature deaths and mitigating long-term economic impacts
The results of a trial that found dexamethasone reduced the risk of death in extremely ill coronavirus patients have yet to be published, but some doctors are already embracing them
Vaccines and drugs drove a century of progress, but today’s contagions thrive on inequality
It could be the second human disease we eradicate—but if we don’t finish the job, resurgence is possible
Despite calls for more rigorous clinical trials, the Food and Drug Administration has granted an emergency authorization for the therapy
Late-stage clinical trials of the first two coronavirus vaccine candidates in the U.S. plan to recruit 60,000 Americans
A preexisting drug could buy time for snakebite treatment
Originally published in February 1955
Teams are starting to test vaccines using messenger RNA or chimpanzee cold viruses to inoculate humans. Will their benefits last?
The decline seen in some studies is normal, experts say. But scientists must wait to see whether infection confers long-term protection
Support science journalism.
Thanks for reading Scientific American. Knowledge awaits.
Already a subscriber? Sign in.
Thanks for reading Scientific American. Create your free account or Sign in to continue.
Create Account